tbuckley/cabot-search huggingface dataset:
Lower-Extremity Arterial Emboli From Ulcerating Atherosclerotic Plaques
Authors: Richard F. Kempczinski
Journal: JAMA (1979)

Ten cases of lower-extremity emboli originated from proximal, ulcerated atherosclerotic plaques. Two distinct clinical presentations were seen. Embolization of cholesterol-rich debris was usually widespread and lodged in terminal arteries, producing either focal digital ischemia or livedo reticularis of the extremity. By contrast, thrombi arising from mural erosions were larger and produced a picture indistinguishable from emboli of cardiac origin. Biplanar aortography was essential in making the correct diagnosis. Anticoagulation has not prevented recurrent embolization. Endarterectomy or graft replacement of the diseased arterial segment is the preferred method of treatment. Lumbar sympathectomy is a useful adjunct when persistent cutaneous ischemia is present. (<i>JAMA</i>241:807-810, 1979)
Transplantation — A Medical Miracle of the 20th Century
Authors: Peter J. Morris
Journal: New England Journal of Medicine (2004)

Fifty years ago, on December 23, 1954, a kidney was transplanted from one healthy identical twin to his twin who was dying of renal disease. The surgery was performed at the Peter Bent Brigham Hospital in Boston, and John Merrill, Joseph Murray, and Hartwell Harrison1,2 led the clinical team. The operation was successful, renal function was restored in the recipient (although he would later have both his own kidneys removed in order to control hypertension), and the donor suffered no ill effects. This was the first successful transplantation, performed against a background of failure. For this reason, it created . . .
Message from the President of the Endoscopy Section of the Hellenic Society of Gastroenterology
Authors: D. Soutos
Journal: Endoscopy (2003)

The Endoscopy Section of the Hellenic Society of Gastroenterology is greatly honored to become an Affiliated Member of the Journal Endoscopy. We are looking forward to productive collaboration and believe that the excellent Journal's scientific articles will be of great help to improve standards of education and research of the members of our Section. We do hope that our members will be able to contribute with scientific research published in Endoscopy.
Plasminogen Activator and Its Inhibitor in Cancer Patients Treated With Tumor Necrosis Factor
Authors: T. F. Logan, M. A. Virji, W. E. Gooding, F. A. Bontempo, M. S. Ernstoff, J. M. Kirkwood
Journal: JNCI Journal of the National Cancer Institute (1992)

Journal Article Plasminogen Activator and Its Inhibitor in Cancer Patients Treated With Tumor Necrosis Factor Get access Theodore F. Logan, Theodore F. Logan * 1Division of Medical Oncology, Department of Medicine, University of Pittsburgh, and Pittsburgh Cancer InstitutePittsburgh, Pa. Present address : M. S. Ernstoff, Dartmouth-Hitchcock Medical Center, Section of Hematology/Oncology, Department of Medicine, Hanover, N.H. Search for other works by this author on: Oxford Academic PubMed Google Scholar Mohamed A. Virji, Mohamed A. Virji 2Department of Pathology, University of Pittsburgh, and Pittsburgh Cancer Institute Search for other works by this author on: Oxford Academic PubMed Google Scholar William E. Gooding, William E. Gooding 3Pittsburgh Cancer Institute Search for other works by this author on: Oxford Academic PubMed Google Scholar Franklin A. Bontempo, Franklin A. Bontempo 4Divisions of Medical Oncology and Hematology, Department of Medicine, University of Pittsburgh Search for other works by this author on: Oxford Academic PubMed Google Scholar Marc S. Ernstoff, Marc S. Ernstoff 1Division of Medical Oncology, Department of Medicine, University of Pittsburgh, and Pittsburgh Cancer InstitutePittsburgh, Pa. Search for other works by this author on: Oxford Academic PubMed Google Scholar John M. Kirkwood John M. Kirkwood 1Division of Medical Oncology, Department of Medicine, University of Pittsburgh, and Pittsburgh Cancer InstitutePittsburgh, Pa. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 23, 2 December 1992, Pages 1802–1810, https://doi.org/10.1093/jnci/84.23.1802 Published: 02 December 1992 Article history Received: 02 April 1992 Revision received: 26 August 1992 Accepted: 15 September 1992 Published: 02 December 1992
Carcinoma of bile ducts in husband and wife.
Authors: C F McCarthy, H J Espiner
Journal: Gut (1969)

Carcinoma of the bile duct is not a common tumour.Its incidence in postmortem studies is from 0.012% (Bolli, quoted by Sako, Seitzinger, and Garside, 1957) to 0.85 % (Von Berency, quoted by Mohardt, 1939).Neither is carcinoma of the ampulla of Vater common.In a 26-year period at the New York Hospital and the Cornell Medical Center, Thorbjarnarson (1959) saw 31 patients with carci- noma of the bile ducts and 20 with carcinoma of the ampulla of Vater.Neibling, Dockerty, and Waugh (1949) in a 10-year period at the Mayo Clinic, during which 14,000 operations were performed on the biliary tract, saw 66 instances of bile duct cancer and 44 of the ampulla of Vater.The Registrar General's figures for England and Wales, 1966 (General Register Office, 1967), indicate that in the years 1958 to 1966 1,000 to 1,200 people died each year of malignant tumours of the biliary tree, including carcinoma of the gall bladder.
A Case of Traumatic Tetanus which Recovered under Antitoxin Injections
Authors: H. L. Evans
Journal: BMJ (1894)

Condition about the same.At7P.m. 2.25grammes of antitoxin were injected, but were not followed by the small doses.July 31st.Patient's condition decidedly better.Spasms and pain confined chiefly to the right leg.Cough is still very troublesome, owing to the difficulty in ejecting the mucus.Although the injured finger was quite healed, it was considered safer to amputate it.Patient was anaesthetised with chloroform, and had to be placed very deeply under its influence before the rigidity of the muscles began to disappear.In the trunk and abdomen the rigidity never completely disappeared.While under the anaesthetic, another dose of antitoxin (2.25 grammes) was injected.August 1st.Patient had a much better night, and the tem- perature began to fall rapidly.From 10.30 A.M. to 9.30 P.M. he had no painful spasms; cough still very troublesome.August 2nd.Improvement continued until 2 P.M. but then he became very restless; more muscular rigidity and an increase in the painful spasms; considerable headache.August 3rd.Patient's condition slightly worse; had a very bad night, chiefly owing to the troublesome cough; very few spasms.No antitoxin was given as the stock was exhausted, and no more could be obtained until August 7th.August 4th to 6th.Patient much better; cough less troublesome; no spasms; sleeping well.Temperature be- tween 990 and 100°.August 7th.Patient in about the same condition excepting that occasionally there were a few spasms.Between 11 A.i. and 3 P.M. there were several painful spasms, and at 7 P.M. 2.25 grammes of antitoxin were injected.Between 8 P.M. and 10 P.M. there were severe spasms.August 8th.Good sleep obtained; had two spasms at 6 A.3;. perspiring freely; patient complains of throat feeling sore and swollen; muscles of legs and trunk still rigid; mouth can be opened about 1 inch.August 9th to August 16th.The tetanic symptoms gradu- ally improved; the temperature varied between 990 and 1030, and soreness of throat still felt.So far as examination of the throat was possible, nothing abnormal could be seen.August 17th to August 24th.Patient's general condition good; temperature still high occasionally (1020 F.).August 25th to September 4th.Steady improvement main- tained; all signs of tetanushave disappeared.Patient rapidly gaining strength and taking food well.
Developments in Aerospace Medicine and Association with Preventive Medicine
Authors: Otis O. Benson
Journal: JAMA (1960)

The development of rocketry has, for the first time, made it possible for man to leave the environs of the earth's atmosphere. It has extended the arts and sciences of aviation into space and aviation medicine into space medicine. The progress is exemplified in Project Mercury, which is to place a manned capsule on top of an intercontinental ballistic missile rocket. Concurrently with these developments, an entirely new generation of stressors with their resultant stresses have presented themselves for solution. A few of the stressors are vibration, noise, weightlessness, and the toxic and corrosive qualities of the rocket fuels and oxidizers. Solutions of the many problems require close association with more conventional aspects of preventive medicine.
Identification of human pulmonary alkaline phosphatase isoenzymes.
Authors: A Capelli, C G Cerutti, M Lusuardi, C F Donner
Journal: American Journal of Respiratory and Critical Care Medicine (1997)

An increase of alkaline phosphatase (ALP) activity has been observed in the bronchoalveolar lavage fluid (BALF) of patients affected by pulmonary fibrosis in chronic interstitial lung disorders. To characterize the ALP isoenzymes in such cases, we used gel filtration, agarose gel electrophoresis, heat and amino acid inhibition assays, wheat-germ agglutinin (WGA) precipitation, and an immunoassay specific for the bone-isoform of ALP. Only one anodic band representing a high-molecular-weight isoform of ALP (Mr approximately 2,000 kDa) was observed on electrophoresis of BALF. The inhibition assay results were consistent for a tissue-nonspecific isoenzyme sensitive to a temperature of 56 degrees C (71.9 +/- 2.5% inhibition) and to homoarginine (65.7 +/- 1.9%), and resistant to L-phenylalanine and L-leucine. Less than 13% of ALP activity was heat-stable. After incubation of BALF specimens with glycosyl-phosphatidylinositol-phospholipase D plus Nonidet P-40, or with phosphatidylinositol-phospholipase C alone, an electrophoretic cathodic band (Mr approximately 220 kDa) appeared near the bone band of a standard serum. With the WGA assay, 84.4 +/- 3.3% of ALP precipitated and the band disappeared. After immunoassay for the bone isoform, a mean of less than 5% enzyme activity was measured. We conclude that the ALP found in BALF is a pulmonary isoform of a tissue nonspecific isoenzyme.
Hyperdiploid Acute Lymphoblastic Leukemia With 51 to 65 Chromosomes: A Distinct Biological Entity With a Marked Propensity to Undergo Apoptosis
Authors: Chikako Ito, Masa-aki Kumagai, Atsushi Manabe, Elaine Coustan-Smith, Susana C. Raimondi, Frederick G. Behm, K. Gopal Murti, Jeffrey E. Rubnitz, Ching-Hon Pui, Dario Campana
Journal: Blood (1999)
Utility of Right Ventricular Tei Index in the Noninvasive Evaluation of Chronic Thromboembolic Pulmonary Hypertension Before and After Pulmonary Thromboendarterectomy
Authors: Daniel G. Blanchard, Philip J. Malouf, Swaminatha V. Gurudevan, William R. Auger, Michael M. Madani, Patricia Thistlethwaite, Thomas J. Waltman, Lori B. Daniels, Ajit B. Raisinghani, Anthony N. DeMaria
Journal: JACC. Cardiovascular imaging (2009)
A Novel Tumor-Promoting Function Residing in the 5′ Non-coding Region of vascular endothelial growth factor mRNA
Authors: Kiyoshi Masuda, Shigetada Teshima-Kondo, Mina Mukaijo, Naoko Yamagishi, Yoshiko Nishikawa, Kensei Nishida, Tomoko Kawai, Kazuhito Rokutan
Journal: PLoS Medicine (2008)

Background Vascular endothelial growth factor-A (VEGF) is one of the key regulators of tumor development, hence it is considered to be an important therapeutic target for cancer treatment. However, clinical trials have suggested that anti-VEGF monotherapy was less effective than standard chemotherapy. On the basis of the evidence, we hypothesized that vegf mRNA may have unrecognized function(s) in cancer cells. Methods and Findings Knockdown of VEGF with vegf-targeting small-interfering (si) RNAs increased susceptibility of human colon cancer cell line (HCT116) to apoptosis caused with 5-fluorouracil, etoposide, or doxorubicin. Recombinant human VEGF165 did not completely inhibit this apoptosis. Conversely, overexpression of VEGF165 increased resistance to anti-cancer drug-induced apoptosis, while an anti-VEGF165-neutralizing antibody did not completely block the resistance. We prepared plasmids encoding full-length vegf mRNA with mutation of signal sequence, vegf mRNAs lacking untranslated regions (UTRs), or mutated 5′UTRs. Using these plasmids, we revealed that the 5′UTR of vegf mRNA possessed anti-apoptotic activity. The 5′UTR-mediated activity was not affected by a protein synthesis inhibitor, cycloheximide. We established HCT116 clones stably expressing either the vegf 5′UTR or the mutated 5′UTR. The clones expressing the 5′UTR, but not the mutated one, showed increased anchorage-independent growth in vitro and formed progressive tumors when implanted in athymic nude mice. Microarray and quantitative real-time PCR analyses indicated that the vegf 5′UTR-expressing tumors had up-regulated anti-apoptotic genes, multidrug-resistant genes, and growth-promoting genes, while pro-apoptotic genes were down-regulated. Notably, expression of signal transducers and activators of transcription 1 (STAT1) was markedly repressed in the 5′UTR-expressing tumors, resulting in down-regulation of a STAT1-responsive cluster of genes (43 genes). As a result, the tumors did not respond to interferon (IFN)α therapy at all. We showed that stable silencing of endogenous vegf mRNA in HCT116 cells enhanced both STAT1 expression and IFNα responses. Conclusions These findings suggest that cancer cells have a survival system that is regulated by vegf mRNA and imply that both vegf mRNA and its protein may synergistically promote the malignancy of tumor cells. Therefore, combination of anti-vegf transcript strategies, such as siRNA-based gene silencing, with anti-VEGF antibody treatment may improve anti-cancer therapies that target VEGF.
Moulded baby syndrome and unilateral "tight" hips.
Authors: C Good, G Walker
Journal: BMJ (1983)

Naltrexone is used as an off-label treatment in low doses for several chronic immune-modulated disorders in many countries. Although only small-scale clinical trials have been performed, these suggest efficacy in several diseases including Crohn’s disease, fibromyalgia and Gulf War Illness. Despite numerous internet reports of response to low-dose naltrexone (LDN), no clinical trials exist in people with chronic fatigue syndrome. This condition is characterised by chronic profound fatigue, postexertional malaise, pain and autonomic and neurocognitive disturbances. This series of three case reports compiled by people with long-term ill-health due to chronic fatigue syndrome shows the range of responses they observed when taking LDN, from life changing to a reduction in some symptoms only. Treatment doses ranged from 4 to 12 mg. Clinical trials may be warranted to explore the potential use of naltrexone in people with these debilitating illnesses which currently have no licensed treatments available.
Fasts after bariatric surgery
Authors: F. Chan, C. Slater, A. A. Syed
Journal: BMJ (2010)

The requirement to observe a total fast (all forms of nourishment including liquids) during daylight hours in the month of Ramadan poses a great challenge in the management of people who have undergone bariatric surgery.1 Bariatric surgery is increasingly performed for the correction of morbid obesity, particularly in people with comorbid conditions …
634 HIGH NT-PRO-BNP LEVELS ARE ASSOCIATED WITH CARDIAC STRUCTURAL CHANGES IN PATIENTS WITH ADVANCED LIVER DISEASE
Authors: A. Licata, C. Genco, S. Corrao, M. Cardillo, F. Massenti, V. Calvaruso, C. Cammá, G. Licata, A. Craxí
Journal: Journal of Hepatology (2012)
Toxic Effects of Marine Plywood
Authors: Glenn Gidseg
Journal: JAMA (1985)

To the Editor.—  I read with interest the recent article regarding toxic effects from burning arsenic-treated (pressure-treated) wood. 1 I recently had a bulkhead installed using such wood. Discussion with the builders indicated that they suffered from rough and irritated hands and had irritation of other parts of their body that were routinely in contact with the wood during construction. They usually did not wear gloves. This is clearly an effect of the chemicals contained in the wood, most notably arsenic, and is not usually seen in carpenters not using arsenic-treated wood. The effects may be accentuated in marine construction use, with the recent introduction of 1.13-kg treated wood. This wood has ten times the amount of chemicals found in the usual 0.11-kg pressure-treated wood used in land construction, the type most likely burned by the family in the aforementioned article. I suggest that appropriate warnings be distributed to lumber
Lesson of the year
Authors: G. Dunea
Journal: BMJ (1997)

The scene is still set in the bustling city of Rhinoceros, verdant and picturesque at the tip of the Potawatomi peninsula. Here we find an abundance of delivered health care, managed care, and even mismanaged care. Here it came to pass that a middle aged woman was sent up to the ward from the emergency room with a diagnosis of confusional state and fractured ribs.

Confusing indeed was the situation at the bedside, where occasional patients are still being evaluated without the aid of computer generated algorithms and even more rarely (or less interestingly) without the benefit of a multidisciplinary conference. But the woman was in great pain, drowsy from analgesics, the history difficult to disentangle. The intern …
Abstract 4192: Role of NF-κB regulators A20 and CARD11 in middle eastern diffuse large B cell lymphoma
Authors: Jehad Abubaker, Prashant Bavi, Zeenath Jehan, Wael Al-Haqawi, Mehar Sultana, Sameer M. Belgaumi, Sarah Siraj, Dahish Ajarim, Fouad Al-Dayel, Shahab Uddin, Khawla S. Al-Kuraya
Journal: Cancer Research (2011)

Abstract Aberrant NF-κB regulation has been observed in many hematopoietic malignancies including diffuse large B cell lymphoma (DLBCL). NF-κB gene plays a role in lymphomagenesis through the transcriptional activation of genes associated with cell proliferation, angiogenesis, metastasis, tumor promotion, inflammation and suppression of apoptosis. CARD11 and A20 genes are known positive and negative regulators of the NF-kB activation pathway and can alternate the NF-kB activity. Considering the potential therapeutic utility of targeting NF-kB and its key modulators, we studied CARD11 genetic alterations (mutations and amplifications), A20 mutations, and immunohistochemical expressions of A20 and CARD11 protein in 150 DLBCL samples. Incidence of CARD11 and A20 mutations was 10.7% and 15.3% of respectively. NF-kB activation was significantly associated with A20 mutation (p=0.0456) thereby highlighting the role of A20 as a tumor suppressor gene and its role in NF-kB inhibition. Interestingly, CARD11 amplification was seen in a significant proportion of the DLBCL (23%) and was linked to NFkB activation (p = 0.0111). A poor overall survival was noted in the DLBCL harboring A20 mutations (p=0.0491) and also in the DLBCL showing presence of CARD11 gene amplification (p=0.0588). Our study highlights the role of CARD11 gene amplifications as a novel mechanism for NF-kB activation and demonstrates clinico-pathological significance of CARD11 and A20 alterations in Middle Eastern DLBCL. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4192. doi:10.1158/1538-7445.AM2011-4192
Pediatric Renal-Replacement Therapy — Coming of Age
Authors: Dawn S. Milliner
Journal: New England Journal of Medicine (2004)

Before the middle of the 20th century, the prospect that a child with end-stage renal disease (ESRD) would reach adulthood was essentially nil. Once dialysis and transplantation became available, that death sentence was lifted, as increasing numbers of children with ESRD were offered renal-replacement therapy. Now, most can expect to live for many years. The time course of this improvement in prognosis is reflected in the data from the Australia and New Zealand Dialysis and Transplant Registry presented by McDonald and Craig in this issue of the Journal (pages 2654–2662). These authors examined the long-term survival of children and adolescents . . .
PEGylation markedly enhances the in vivo potency of recombinant human non-glycosylated erythropoietin: A comparison with glycosylated erythropoietin
Authors: Yin-Jue Wang, Su-Juan Hao, Yong-Dong Liu, Tao Hu, Gui-Feng Zhang, Xuan Zhang, Qing-Sheng Qi, Guang-Hui Ma, Zhi-Guo Su
Journal: Journal of Controlled Release (2010)
Fero-Grad-500 Filmtab®
Authors: GARY D. GENTZKOW
Journal: Annals of Internal Medicine (1976)

Comments1 November 1976Fero-Grad-500 Filmtab®GARY D. GENTZKOW, M.D., JAMES D. STECK, M.S., R.PH.GARY D. GENTZKOW, M.D.Search for more papers by this author, JAMES D. STECK, M.S., R.PH.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-85-5-683_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Dr. Perillie's recent letter in the "Comments and Corrections" section (Ann Intern Med 85:125, 1976) was critical of this journal for publishing an advertisement for our product, Fero-Grad-500 Filmtab® (controlled release iron and 500-mg vitamin C, Abbott Laboratories). He implied that sustained-release iron preparations are ineffective in the treatment of iron deficiency.We are not qualified to comment on sustained-release iron preparations produced by other companies. As for Fero-Grad-500 Filmtab, however, we believe substantial evidence exists showing that this produce is efficacious in the treatment of iron deficiency. Fero-Grad-500 Filmtab contains the equivalent of 105 mg of...References1. BERRYMANMCANDREWENDICOTT GMC: Human gastric studies of iron release from a controlled-release form of ferrous sulfate versus the capsule form. Curr Ther Res 4:378-383, 1962 MedlineGoogle Scholar2. LAYRISSE M: The utilization of iron from a controlled-release dose form. Curr Ther Res 5:232-237, 1963 Google Scholar3. BURSLEMPOLLERWACKS RLH: A trial of slow release ferrous sulphate (Ferrogradumet®) in prevention of iron deficiency in pregnancy. Acta Haematol 40:200-204, 1968 CrossrefMedlineGoogle Scholar4. ZIEHMLIKOS DJ: Treatment of anemia in obstetric and gynecologic patients with sustained-release and conventional iron preparations. Obstet Gynecol 28:430-434, 1966 MedlineGoogle Scholar5. BRISEHALLBERG HL: Effect of ascorbic acid on iron absorption. Acta Med Scand (suppl 376) 171:51-58, 1962 Google Scholar6. MCCURDYDERN PR: Some therapeutic implications of ferrous sulfate-ascorbic acid mixtures. Amer J Clin Nutr 21:284-288, 1968 CrossrefMedlineGoogle Scholar7. BONNARGOLDBERGSMITH JAJ: Do pregnant women take their iron? Lancet 1:457-458, 1969 CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Department of Medical Services Abbott Laboratories North Chicago, IL 60064 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 November 1976Volume 85, Issue 5Page: 683-684KeywordsIron deficiencyVitamin C Issue Published: 1 November 1976 PDF DownloadLoading ...